Abstract
Purpose
In this pilot study we aimed to examine the association between eyelid fornices triamcinolone injections and clinical activity score in patients with active thyroid orbitopathy.
Methods
Adult patients aged 18 years or older, diagnosed with active thyroid orbitopathy and a clinical activity score ≥3 were recruited to this interventional prospective pilot study between 2010 and 2013. Three upper and lower fornices injections of triamcinolone acetate 20 mg (40 mg/ml) were administered at 4-week intervals. Each patient included was followed up for a period of 6 months. Clinical activity score was estimated at each monthly visit. Extraocular muscle thickness was measured by ultrasound examination at entrance and at the last visit.
Results
Eleven eyes of seven patients were included in our study. Initial clinical activity score was 3.81 ± 1.80 and fell to 0.63 ± 0.72 during a 6-month follow-up. There was a significant difference in clinical activity score between the baseline examination and the following visits (p-value < 0.0001). Ultrasound examination showed a significant decrease in medial and lateral rectus muscle thickness following treatment; median difference −0.93 and −0.58, respectively (p-value < 0.005). Lid retraction was reduced by the treatment. Side effects included a transitory increase in intraocular pressure in one patient, which was controlled with topical medication.
Conclusions
In this pilot study a series of three separate triamcinolone fornix injections at 4-week intervals reduces the inflammatory effects of thyroid orbitopathy, as measured by clinical activity score. The treatment was simple, effective, and safe eliminating the side effects associated with systemic corticosteroid use.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Warwar RE (1990) New in-sights into pathogenesis and potential therapeutic options for Graves’ orbitopathy. Curr Opin Ophthalmol 10:358–361
Campbell JC (1989) Immunology of Graves’ ophthalmopathy: retrobulbar histology and histochemistry. Acta Endocrinol 121:9–16
Ohtsuka K, Hashimoto M (1999) H-magnetic resonance spectroscopy of retrobulbar tissue in Graves’ ophthalmopathy. Am J Ophthalmol 128:715–719
Kahaly G (1994) Immunohistochemical staining of retrobulbar adipose tissue in Graves’ ophthalmopathy. Clin Immunol Immunopathol 73:53–62
Mourits M, Koornneef L, Wiersinga W et al (1989) Clinical criteria for the assessment of disease activity in Graves’ ophthalmopathy: a novel approach. Brit J Ophthalmol 74:639–644
Bartalena L, Marcocci C, Bogazzi F et al (1991) Glucocorticoid therapy of Graves’ ophthalmopathy. Exp Clin Endocrinol 97:320
Bartalena L, Marcocci C, Pinchera A (1997) Treating severe Graves’ ophthalmopathy. Baillieres Clin Endocrinol Metab 11:521–536
Tagami T, Tanaka K, Sugawa H (1996) High-dose intravenous steroid pulse therapy in thyroid-associated ophthalmopathy. Endocr J 43:689–699
Ohtsuka-Sato A, Kawaguchi S, Hashimoto M et al (2003) Effect of steroid pulse therapy with and without orbital radiotherapy on Graves’ Ophthalmopathy. Am J Ophthalmol 135:285–290
Gebertt S (1961) Depot-methylprednisolone for subconjunctival and retrobulbar injections. Lancet 2:344–345
Ebner R, Devoto MH, Weil D et al (2004) Treatment of thyroid associated ophthalmopathy with periocular injections of triamcinolone. Br J Ophthalmol 88:1380–1386
Goldberg RA (2004) Orbital steroid injections. Br J Ophthalmol 88:1359–1360
Gupta OP, Boynton JR, Sabini P et al (2003) Proptosis after retrobulbar corticosteroid injections. Ophthalmology 110:443–447
Smith JR, George RK, Rosenbaum JT (2002) Lower eyelid herniation of orbital fat may complicate periocular corticosteroid injection. Am J Ophthalmol 133:845–847
Bordaberry M, Marques DL, Pereira-Lima JC et al (2009) Repeated peribulbar injections of triamcinolone acetonide: a successful and safe treatment for moderate to severe Graves’ ophthalmopathy. Acta Ophthalmol 87:58–64
Alkawas A, Hussein A, Shahien E (2010) Orbital steroid injection versus oral steroid therapy in management of thyroid-related ophthalmopathy. Clin Exp Ophthalmol 38:692–697
Bartalena L, Baldeschi L, Dickinson A et al (2008) Consensus statement of the European Group on Graves’ orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 158:273–285
Lee S, Rim T, Jang S et al (2013) Treatment of upper eyelid retraction related to thyroid-assosciated ophthalmopathy using subconjunctival triamcinolone injections. Graefes Arch Exp Ophthlamol 251:261–270
Xu D, Liu Y, Xu H et al (2012) Repeated triamcinolone acetonide injection in the treatment of upper-lid retraction in patients with thyroid-associated ophthalmopathy. Can J Ophthalmol 47:34–41
Chee E, Chee S-P (2008) Subconjunctival injection of trimacinolone in the treatment of lid retraction of patients with thyroid eye disease: a case series. Eye 22:311–315
Lee J, Lee H, Park M et al (2012) Subconjunctival injection of Triamcinolone for the treatment of upper lid retraction associated with thyroid eye disease. J Craniofac Surg 23:1755–1758
Acknowledgments
The statistical analysis was done by the statistician Naama Schwartz (Haemek Medical Center–Afula, Israel).
The authors declare that we have no conflict of interest and no funds were received for this work.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hamed-Azzam, S., Mukari, A., Feldman, I. et al. Fornix triamcinolone injection for thyroid orbitopathy. Graefes Arch Clin Exp Ophthalmol 253, 811–816 (2015). https://doi.org/10.1007/s00417-015-2957-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00417-015-2957-7